Prenatal Cannabis Use Disorder Increases Risk for Neurodevelopmental Disorders
By Lori Solomon HealthDay Reporter
MONDAY, April 15, 2024 -- Prenatal cannabis use disorder (CUD) is associated with a higher risk for subsequent neurodevelopmental disorders in offspring, according to a study presented at the annual congress of the European Psychiatric Association, held from April 6 to 9 in Budapest, Hungary.
Abay Woday Tadesse, from Curtin University in Perth, Australia, and colleagues examined the association between prenatal CUD and neurodevelopmental disorders in offspring. The analysis included administrative health data from 222,569 mother-offspring pairs (live births from January 2003 to December 2005).
The researchers found that offspring from mothers with prenatal CUD had an increased risk for attention-deficit/hyperactivity disorder (ADHD; adjusted risk ratio [aRR], 1.98), autism spectrum disorder (ASD; aRR, 1.94), and intellectual disability (ID; aRR, 1.46) compared with nonexposed offspring. There was also a significant interaction effect observed for CUD during pregnancy and maternal smoking with the risk for childhood neurodevelopmental disorders (ADHD: RR, 5.62; ASD: RR, 2.72; and ID: RR, 2.84). Lastly, there were significant associations between CUD and ADHD, ASD, and ID when interacting with low birth weight and premature birth.
"The increased risk of neurodevelopmental disorders in children of mothers diagnosed with prenatal cannabis use that we have observed in this study underscores the critical needs for preventive measures, including preconception counselling, to mitigate the potential adverse outcomes," Tadesse said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
ADHD Meds May Help Control Opioid Use Disorder in Pregnancy
TUESDAY, June 25, 2024 -- Psychostimulants may help opioid use disorder (OUD) outcomes in pregnant women, according to a study published online June 11 in Nature Mental...
New Neurocognitive/Functional Morbidity Explored in SARS-CoV-2, MIS-C
WEDNESDAY, June 12, 2024 -- Children with acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and multisystem inflammatory syndrome in children (MIS-C) with severe...
FDA Approves First Liquid, Nonstimulant ADHD Treatment, Onyda XR
MONDAY, June 3, 2024 -- The U.S. Food and Drug Administration has approved once-daily Onyda XR (clonidine hydrochloride) as the first liquid, nonstimulant treatment for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.